Changes in US stocks | HCM.US (HCM.US) rose more than 3% to submit a new drug marketing application for Warissa and Teresa combination therapy to the FDA

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that on Wednesday, HCM.US (HCM.US) rose more than 3% to $14.59. According to the news, on September 29, Hehuang Pharmaceutical issued an announcement stating that AstraZeneca has submitted a marketing application for a new drug with Warisha and Teresa combination therapy to the US FDA to treat patients with locally advanced or metastatic non-small cell lung cancer with excessive MET expression or amplification during or after EGFR TKI treatment. The SAFFRON global phase III study showed improvements in both progression-free survival and overall survival.